Methods
Patients and Data Collection
Definitions
Outcomes
Statistical Analysis
Results
Baseline and Treatment
(N = 68) | |
---|---|
Baseline | |
Female sex, no. (%) | 32 (47.1) |
Age, median (IQR), year | 60 (52–67) |
Mean (SD), year | 58.9 (10.6) |
Body-Mass-Index, median (IQR), kg/m2 | 24 (22–26.5) |
Mean (SD), kg/m2 | 24.3 (3.6) |
ASA-classification, no. (%) | |
ASA-1 | 12 (17.7) |
ASA-2 | 50 (73.5) |
ASA-3 | 6 (8.8) |
Abdominal surgery history ≥ 1, no. (%) | 21 (32.8) |
Preoperative tumor characteristics | |
Additional organ involvement*, no. (%) | |
Stomach | 6 (8.8) |
Liver | 1 (1.5) |
Kidney | 3 (4.4) |
Adrenal gland | 5 (7.4) |
Additional vascular involvement, no. (%) | |
Hepatic artery | 8 (11.8) |
Superior mesenteric artery | 7 (10.3) |
Portal vein | 6 (8.8) |
Superior mesenteric vein | 9 (13.2) |
Preoperative tumor size, median (IQR), mm | 37 (30–50) |
Mean (SD), mm | 43 (33) |
AJCC staging**, no. (%) | |
T-stage ≥ 3 | 62 (95.4) |
N-stage > 0 | 20 (29.9) |
M-stage > 0 | 1 (1.5) |
(N = 68) | |
---|---|
Preoperative | |
Neoadjuvant treatment, no. (%) | |
Chemotherapy | 15 (22.1) |
Chemoradiotherapy | 19 (27.9) |
Preoperative hepatic artery embolization, no. (%) | 15 (22.1) |
Operative | |
Intent to perform DP-CAR | 55 (80.9) |
Operative time, median (IQR), min | 328 (244–415) |
Mean (SD), min | 341 (124) |
Additional organs resected*, no. (%) | |
Stomach | 7 (10.3) |
Liver | 3 (4.4) |
Kidney | 3 (4.4) |
Adrenal gland | 15 (22.1) |
Additional vessels resected, no. (%) | |
Right/left hepatic artery | 1 (1.5) |
Superior mesenteric artery | 1 (1.5) |
Portal vein | 6 (8.8) |
Superior mesenteric vein | 10 (14.7) |
Vascular reconstruction, no. (%) | |
Common hepatic artery | 9 (13.2) |
Superior mesenteric artery | 1 (1.5) |
Portal vein | 6 (8.8) |
Superior mesenteric vein | 3 (4.4) |
Estimated blood loss, median (IQR), mL | 500 (350–1300) |
Mean (SD), mL | 922 (893) |
Blood transfusion for bleeding (< 72 h), no. (%) | 20 (31.3) |
Postoperative | |
Adjuvant treatment, no. (%) | |
Chemotherapy | 41 (60.3) |
Radiotherapy | 2 (2.9) |
Chemoradiotherapy | 2 (2.9) |
Short-term Outcomes
(N = 68) | |
---|---|
Outcomes | |
Mortality within 30 days, no. (%) | 7 (10.3) |
Mortality within 90 days, no. (%) | 11 (16.4) |
Complications within 90 days, no. (%) | |
Clavien-Dindo 3a–4b | 17 (25) |
Post-pancreatectomy hemorrhage*, no. (%) | 6 (8.8) |
Liver ischemia | 12 (17.7) |
Abdominal cavity infection, no. (%) | 4 (5.9) |
Pancreatic fistula grade B/C* no. (%) | 14 (20.6) |
Delayed gastric emptying grade B/C*, no. (%) | 11 (17.5) |
Reinterventions, no. (%) | |
Endoscopic intervention, no. (%) | 1 (1.6) |
Radiologic drainage, no. (%) | 9 (14.5) |
Reoperation, no. (%) | 10 (14.7) |
Gastric (wedge) resection for ischemia | 3 |
Hemorrhage repair | 2 |
Re-do vascular anastomosis | 2 |
Gastrojejunostomy for DGE | 1 |
Repair of metastatic colon perforation | 1 |
Peripheral arterial embolectomy | 1 |
Histopathology | |
Malignant etiology, no. (%) | |
PDAC | 62 (91.2) |
Invasive IPMN | 3 (4.4) |
Other malignant diagnosis | 3 (4.4) |
Tumor size, median (IQR), mm | 40 (32–50) |
Mean (SD), mm | 44 (23) |
Resection margin, no. (%) | |
R0 | 36 (54.6) |
R1 | 28 (42.4) |
R2 | 2 (3) |
Lymph nodes harvested, median (IQR), no. | 22 (16–29.5) |
Median (SD), no. | 25 (15) |
Lymph node metastasis, no. (%) | 45 (66.2) |
Length of hospital say, median (IQR), days | 16.5 (11–27) |
Mean (SD), days | 20 (14) |
Unplanned readmission, no. (%) | 9 (13.9) |
Overall survival, median (CI), months | 17 (10–33) |